Navigation Links
Callisto Pharmaceuticals Announces Publication of Research Article,on Atiprimod Preclinical Studies in Mantle Cell Lymphoma

oma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways" by M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, F. Samaniego, J. Romaguera and Q. Yi.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs in pre-clinical development for other significant health care markets, including ulcerative colitis. One of the Company's lead drug candidates, Atiprimod, is in development to treat advanced carcinoid cancer, a neuroendocrine tumor, and relapsed multiple myeloma, a blood cancer. Atiprimod is presently in a Phase II clinical trial in advanced carcinoid cancer patients, and in Phase I/IIa human clinical trials in relapsed or refractory multiple myeloma patients, and advanced cancer patients, respectively. Another anti-cancer drug, L-Annamycin, is being developed as a treatment for forms of relapsed or refractory acute leukemia, a currently incurable blood cancer. Callisto initiated a clinical trial of L- Annamycin in pediatric acute leukemia patients in 1Q 2007 and initiated a trial in adult relapsed or refractory acute lymphoblastic leukemia patients in 4Q 2005. L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Callisto also has drugs in preclinical development for gastro-intestinal inflammation, and cancer. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L- Annamycin, respectively. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. More information is availa
'"/>




Page: 1 2 3

Related medicine technology :

1. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:4/24/2015)... HANOVER, N.J. , April 24, 2015  Novartis Pharmaceuticals ... for the second year in a row on the annual ... results of its 2015 Top 50 Companies for Diversity on ... York, NY . NPC also ranked second on the ... the Top 10 Companies for Employee Resource Groups list. ...
(Date:4/24/2015)... T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"), a ... products and a licensed producer ("LP") to cultivate marijuana ... Canada ) ("MMPR"), is pleased to announce that ... the transaction announced on March 11, 2015 with Medna ... a total of 20,156,790 common shares of T-Bird (45% ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ... Drug Administration (FDA) has accepted its New Drug Application ... interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir ... treatment of adults with chronic genotype 4 (GT4) hepatitis ... the first all-oral, interferon-free therapy being evaluated by the ...
Breaking Medicine Technology:Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 3Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 4T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/25/2015)... 25, 2015 For thirteen years, the Twin ... protection education event in the nation! This year, on May ... Group, US to take DI Day on the road by ... Davidson, CLU, ChFC, RHU, DIA, CLTC, Chief Executive Officer at ... reflects on the change by stating, "The first Twin Cities ...
(Date:4/24/2015)... New York, NY (PRWEB) April 24, 2015 ... upscale sober living residence in Westchester County. Just 35 ... to help transition individuals back into everyday life while ... for Thursday, May 7, 2015, will allow therapists, doctors ... living areas and learn more about the opportunities offered ...
(Date:4/24/2015)... As the nation recognizes the Month of the ... young men and women, the “Alaska – Forget Me ... presents a special training session on Adverse Childhood Experiences ... understanding of the effect of childhood trauma and, in ... and military – who provide services and support to ...
(Date:4/24/2015)... April 24, 2015 Carvers' goal ... have a successful biking day in Breck. , ... five minutes walking distance from Breckenridge, this family-owned ... in both Breckenridge bike rentals ( http://www.breckenridgeskishop.com/en/rent-equipment ) ... offer extensive bike rentals in May 2015. With ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Lipitor ... forward in the federal multidistrict litigation underway in ... to court documents, the parties involved in the ... 16th detailing, among other things, preparation for the ... counsel for both plaintiffs and defendants have conducted ...
Breaking Medicine News(10 mins):Health News:Secura Consultants Takes DI Day On The Road 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Carvers Breckenridge Bike Rentals Offers Demo Mountain, Tandem, Bike Path Cruiser & JR. Bikes in May 2015 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3
... Silicone breast implants went through a long period of relative dormancy ... Now, two years after the U.S. Food and Drug Administration approved ... plastic surgeon Richard L. Zeff, MD comments on why he feels ... ...
... Corticon offers special pricing on patent-pending Dialogs, the premier platform ... ... Redwood City, CA (PRWEB) April 2, ... in model-driven Business Rules Management Systems (BRMS), today announced special ...
... Nurse Training, Inc., provider of nurse training seminars on DVD and online ... ... April 2, 2009 -- Medical Nurse Training, Inc., provider of nurse training ... its website., , ,Medical Nurse Training, Inc. provides DVD and online courses ...
... IT, a national provider of medical documentation services and software, announced ... innovative medical documentation company that serves more than 450 healthcare professionals ... ... (PRWEB) April 2, 2009 -- MD IT , a national ...
... pregnancy, such as morning sickness, fatigue and weight gain, but despite this, ... Gurgle, we offer a guide to women in their early stages of ... ... (PRWEB) April 2, 2009 -- Around half of all women will experience ...
... April 2 In the first,quarter of 2009 (December ... figure of EUR237.3m (Q1 2008: EUR239.1m) almost at the ... world economy. In,the core business, however, sales by the ... The operating result (adjusted EBITDA) ...
Cached Medicine News:Health News:New Hampshire Cosmetic Plastic Surgeon Discusses Silicone Breast Implants after Breast Augmentation becomes No. 1 Cosmetic Surgery Procedure 2Health News:New Hampshire Cosmetic Plastic Surgeon Discusses Silicone Breast Implants after Breast Augmentation becomes No. 1 Cosmetic Surgery Procedure 3Health News:New Hampshire Cosmetic Plastic Surgeon Discusses Silicone Breast Implants after Breast Augmentation becomes No. 1 Cosmetic Surgery Procedure 4Health News:Corticon Shows Business Transformation Potential of Dialogs, The First Intelligent Interactions Platform, at April 23 Webinar 2Health News:Corticon Shows Business Transformation Potential of Dialogs, The First Intelligent Interactions Platform, at April 23 Webinar 3Health News:Medical Nurse Training, Inc. Announces the Launch of Medicalnursetraining.com 2Health News:MD IT Expands in the Northwest with Acquisition of Seattle's Pro Scribe 2Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 2Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 3Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 4Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 5Health News:Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed 2Health News:Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed 3Health News:Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed 4
Adjustable speed vortex with inter-changeable heads , 110 V...
Adjustable speed vortex with inter-changeable heads, 110 V...
... the Mo Bio Vortex Adapter in conjunction with ... procedures. Using the Mo Bio Vortex Adapter ... and Fast Prep machines which offer the same ... ml) centrifuge tubes at one time and will ...
... Vacuum Controller V-800 and water-cooled secondary condenser ... Compact Housing Model V-500 is a ... most vacuum applications. Applications Ideally ... evaporators Laboratory vacuum source for instruments ...
Medicine Products: